JP2023512452A5 - - Google Patents
Info
- Publication number
- JP2023512452A5 JP2023512452A5 JP2022542664A JP2022542664A JP2023512452A5 JP 2023512452 A5 JP2023512452 A5 JP 2023512452A5 JP 2022542664 A JP2022542664 A JP 2022542664A JP 2022542664 A JP2022542664 A JP 2022542664A JP 2023512452 A5 JP2023512452 A5 JP 2023512452A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- cells
- subdomain
- intracellular signaling
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960285P | 2020-01-13 | 2020-01-13 | |
| US62/960,285 | 2020-01-13 | ||
| PCT/US2021/012977 WO2021146147A1 (en) | 2020-01-13 | 2021-01-11 | Bcma-directed cellular immunotherapy compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512452A JP2023512452A (ja) | 2023-03-27 |
| JP2023512452A5 true JP2023512452A5 (https=) | 2024-01-18 |
Family
ID=76864781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542664A Pending JP2023512452A (ja) | 2020-01-13 | 2021-01-11 | Ｂｃｍａ指向性細胞免疫療法組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230028399A1 (https=) |
| EP (1) | EP4090337A4 (https=) |
| JP (1) | JP2023512452A (https=) |
| KR (1) | KR20220128650A (https=) |
| CN (1) | CN115279381A (https=) |
| AU (1) | AU2021207795A1 (https=) |
| CA (1) | CA3164666A1 (https=) |
| IL (1) | IL294518A (https=) |
| MX (1) | MX2022008638A (https=) |
| WO (1) | WO2021146147A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| US20250034268A1 (en) * | 2021-12-07 | 2025-01-30 | Innovent Biologics (Suzhou) Co., Ltd. | Antibody binding to bcma and use thereof |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200613552A (en) * | 2004-08-11 | 2006-05-01 | Hoffmann La Roche | Mutant interleukin-15 polypeptides |
| RU2766608C2 (ru) * | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| DK2956175T3 (da) * | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| BR112019019917A2 (pt) * | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| EP3749770B9 (en) * | 2018-02-09 | 2025-12-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Tethered interleukin-15 and interleukin-21 |
| TWI890660B (zh) * | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN109320615B (zh) * | 2018-09-25 | 2023-09-22 | 上海恒润达生生物科技股份有限公司 | 靶向新型bcma的嵌合抗原受体及其用途 |
| EP3773918A4 (en) * | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
-
2021
- 2021-01-11 AU AU2021207795A patent/AU2021207795A1/en active Pending
- 2021-01-11 EP EP21740869.9A patent/EP4090337A4/en active Pending
- 2021-01-11 JP JP2022542664A patent/JP2023512452A/ja active Pending
- 2021-01-11 WO PCT/US2021/012977 patent/WO2021146147A1/en not_active Ceased
- 2021-01-11 KR KR1020227028061A patent/KR20220128650A/ko active Pending
- 2021-01-11 CA CA3164666A patent/CA3164666A1/en active Pending
- 2021-01-11 IL IL294518A patent/IL294518A/en unknown
- 2021-01-11 CN CN202180019394.3A patent/CN115279381A/zh active Pending
- 2021-01-11 MX MX2022008638A patent/MX2022008638A/es unknown
- 2021-01-11 US US17/758,116 patent/US20230028399A1/en active Pending